Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Loratadine
Sun Pharma UK Ltd
R06AX13
Loratadine
10mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 03040100; GTIN: 5015525162824
If you are pregnant or breast-feeding think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not take One A Day Allergy Tablets if you are pregnant. Do not take One A Day Allergy Tablets if you are breast-feeding. Loratadine is excreted in breast milk. USE IN CHILDREN Frequency not known weight increased Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. or search for MHRA Yellow Card in the This leaflet was last revised December 2017. Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Roletra 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg loratadine. Excipients with known effect: Each tablet also contains 78.25mg lactose monohydrate. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablets White to off-white, round, uncoated tablets debossed with "R" on one side and "10" on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Roletra 10 mg tablets are indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children over the age of 2 years with a body weight more than 30kg. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and children over 12 years of age: 10mg once daily (one tablet once daily) Paediatric population Children 2 to 12 years of age are dosed by weight: Body weight more than 30kg: 10mg once daily (one tablet once daily). Body weight 30kg or less: The 10mg strength tablet is not appropriate in children with a body weight less than 30kg. There are other formulations more suitable for children 2 to 12 years old with body weight 30 kg or less. Safety and efficacy of Roletra 10 mg tablets in children under 2 years of age has not been established. No data are available. Patients with hepatic treatment Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine. An initial dose of 10mg every other day is recommended for adults and children weighing more than 30kg. Patients with renal impairment No dosage adjustments are required in patients with renal insufficiency. Older people No dosage adjustments are required in older people. Method of administration Oral use. The tablet may be taken without regard to mealtime. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Roletra 10 mg Tablets should be administered with Read the complete document